|LETTER TO THE EDITOR
|Year : 2022 | Volume
| Issue : 7 | Page : 131
Anaphylaxis and COVID-19: A clinical issue
Pathum Sookaromdee1, Viroj Wiwanitkit2
1 Private Academic Consultant, Bangkok, Thailand
2 Dr. D.Y. Patil University, Pune, Maharashtra, India
|Date of Submission||19-Dec-2020|
|Date of Decision||08-May-2022|
|Date of Acceptance||12-May-2022|
|Date of Web Publication||14-Jun-2022|
Private Academic Consultant, Bangkok
Source of Support: None, Conflict of Interest: None
|How to cite this article:|
Sookaromdee P, Wiwanitkit V. Anaphylaxis and COVID-19: A clinical issue. Med J DY Patil Vidyapeeth 2022;15, Suppl S1:131
Dear editor, coronavirus disease-2019 (COVID-19) is the current global medical issue. There are several clinical problems related to COVID-19. In clinical immunology, anaphylaxis and COVID-19 are an interesting issue. First, there are some reports on anaphylaxis in patients suffering from COVID-19. From root cause analysis, it is found that there is usually a cause of anaphylaxis such as antibiotics or the alternative trailed COVID-19 therapy by convalescent plasma. Additionally, COVID-19 outbreak results in alteration of normal medical service. Hence, the preparation for emergency telehealth care and home management of a patient with anaphylaxis during the lockdown period is necessary.,,
Finally, anaphylaxis is an important consideration for new COVID-19 vaccines. In addition, anaphylaxis is a possible adverse effect of COVID-19. Although there is no report on this adverse effect of new vaccines in clinical trial reports, there are already some cases in real situations (such as in Alaska, USA). The long-term surveillance of post-launch of COVID-19 vaccines for general use is important. Skin testing might have a role in preventing anaphylaxis if the risk is high for a specific type of vaccine. According to Greenhawt et al., skin testing is important in clarifying the mechanism of anaphylaxis and providing safety advice for the next injection.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Alvarez-Perea A, Baeza ML. Anaphylactic shock following the diagnosis of coronavirus disease 2019. Ann Allergy Asthma Immunol 2020;125:477-8.
Piechotta V, Chai KL, Valk SJ, Doree C, Monsef I, Wood EM, et al
. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: A living systematic review. Cochrane Database Syst Rev 2020;7:CD013600.
Casale TB, Wang J, Nowak-Wegrzyn A. Acute at home management of anaphylaxis during the Covid-19 pandemic. J Allergy Clin Immunol Pract 2020;8:1795-7.
Senna G, Caminati M, Castells M. Editorial: Reconsidering anaphylaxis at the time of COVID-19 pandemic. Curr Opin Allergy Clin Immunol 2020;20:429-30.
Mack DP, Chan ES, Shaker M, Abrams EM, Wang J, Fleischer DM, et al
. Novel approaches to food allergy management during COVID-19 inspire long-term change. J Allergy Clin Immunol Pract 2020;8:2851-7.
Laisuan W. COVID-19 Vaccine anaphylaxis: Current evidence and future approaches. Front Allergy 2021;2:801322. doi: 10.3389/falgy. 2021.801322.